CARAMEL Observational Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age40-60
SponsorBiogipuzkoa Health Research Institute

About this trial

CARAMEL is a project funded by the European Commission under the Horizon Europe programme. Its aim is to develop a personalized prevention approach based on state-of-the-art artificial intelligence models for cardiovascular risk stratification in women aged 40-60 years. These models are trained using large amounts of multi-source data and complemented by digital self-assessment and self-management tools. The CARAMEL consortium brings together a diverse group of 25 organizations, including technology companies and research centers, clinical institutions, as well as experts in ethics, law, and communication.

The CARAMEL-OS study is an observational study aimed at prospectively completing the proposed personalized cardiovascular risk stratification model for women aged 40-60 years that will be developed during the earlier phases of the overall CARAMEL project (https://www.caramel-project.eu/).

The study has a purely observational design, and patient stratification will not entail any clinical intervention. The data collected will be used to complete the design of the personalized stratification model, as well as to develop and validate the performance of the predictive models in an independent prospective cohort, distinct from the retrospective cohort initially used. The performance of the models developed using retrospective data will be assessed in terms of accuracy, discrimination, calibration, and other relevant metrics. In addition, the study will enable the development of new predictive models with short-term prediction horizons, incorporating additional variables that are not available retrospectively.

The study population will be recruited in four European Union countries: Croatia, Spain (Andalusia and The Basque Country - Gipuzkoa), Greece and Lithuania; and in Colombia. A prospective cohort of 3,000 women aged 40-60 will be recruited, with each partner contributing 500 participants.

Eligibility criteria

Qualifiers

Women 40 to 60 years of age, at recruitment.

Ability to understand and complete the required informed consent for the study.

Women who are covered by the corresponding healthcare system operating at each clinical site.

Disqualifiers

Severe comorbidity with less than 24 months life expectancy.

Lack of basic digital skills to use or carry a smartphone and wearable devices.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

3,000 Participants
are grouped into 1 trial group

Sponsors and collaborators

Biogipuzkoa Health Research Institute

Lead sponsor

Fundación Centro de Tecnologías de Interacción Visual y Comunicaciones Vicomtech

Collaborator

Keralty SAS

Collaborator

Particle Summary

Collaborator

iBreve Limited

Collaborator

Magdalena Clinic

Collaborator

Andaluz Health Service

Collaborator

AE. Fundación Pública Andaluza para la gestión de la investigación en salud de Sevilla

Collaborator

Viesoji Istaiga Vilniaus Universiteto Ligonine Santaros Klinikos

Collaborator

Asociación Centro de Investigación Cooperativa en Biociencias

Collaborator

Ulma Medical Technologies S Coop

Collaborator

Smartnanosenose Innovation

Collaborator

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Collaborator